Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Government lawyers reject multiple's legal challenge to cuts

The government's "legal department" has maintained that the Department of Health's (DH) approach to the pharmacy funding cuts was lawful, C+D has learned.

David Reissner, senior healthcare partner at law firm Charles Russell Speechlys, confirmed to C+D today (November 30) that he has received a response from government lawyers regarding his firm's legal challenge to the cuts.

Mr Reissner said the government has maintained that the consultation process to decide the sector's funding has been "lawful" and the impact assessment that underpins the intended cuts "is not flawed". 

Mr Reissner was asked by an unnamed multiple to obtain a senior lawyer's opinion on the lawfulness of the cuts earlier this month.

The client – who still wishes to remain anonymous – is now considering how to proceed, Mr Reissner added.

What do you make of the DH's rejection?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD008473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel